Home
G2GBIO

G2GBIO Market Share Analysis for August 2026

지투지바이오 Biotech company developing sustained release injectables

Industry: N/A

Domaing2gbio.com

Year Founded--

Employees51 - 200

Annual Revenue--

G2GBIO

G2GBIO (including company regionals)

g2gbio.com

See more website traffic and engagement information

Total visits to G2GBIO's top domains

Understand G2GBIO market share and potential market reach.

Total visits last 3 months

Subsidiaries Breakdown

g2gbio.com825

See more with Sales Intelligence

Avg. visit duration in G2GBIO's top domains

Analyze G2GBIO engagement metrics.

Average visit duration last 3 months

Subsidiaries Breakdown

g2gbio.com00:02:31

See more with Sales Intelligence

Avg. pageviews on G2GBIO's top domains

See how G2GBIO keep users engaged, nurture their interest, and encourage them to take the next step.

Average page views last 3 months

Subsidiaries Breakdown

g2gbio.com2.70

See more with Sales Intelligence

G2GBIO top competitors by domain

Top similar sites in August 2026, ranked by their affinity

$fractyl.com$

fractyl.comCompany NameFractyl HealthEmployees51 - 200HQUnited States, Massachusetts, LexingtonAnnual revenue$5M - $10MTotal visits5.6KHealth > Health - Other

Top technologies used by G2GBIO

These are the website technologies, by industry, used by G2GBIO top domains

Widget (3)

reCAPTCHA

Advertising (2)

DoubleClick

Audio Video Media (1)

YouTube

Conversion & Analytics (1)

Naver Analytics

More Technologies

4

See all

News & Signals from G2GBIO

With Similarweb Sales signals alerts, you’ll receive daily updates of recognized buying signals whenever new opportunities or threats arise in your target audience.

NewsG2GBIO Inc. is developing long-acting obesity treatments on Mar 1st '26.Samsung Epis Holdings' two subsidiaries - biopharmaceutical developer Samsung Bioepis and biotechnology platform developer Epis NexLab - teamed up with local biotech G2GBio to develop long-acting obesity treatments by leveraging the latter's microsphere-based drug delivery technology in March.

NewsG2GBIO Inc. is developing long-acting microsphere drug delivery platform.Under this agreement, Epis NexLab and G2GBIO will co-develop a long-acting microsphere drug delivery platform based on G2GBIO's current technology, which includes its Innovative Long-Acting Microsphere Platform or InnoLAMP.